Precisely, ACAT1-mediated GNPAT acetylation could inhibit GNPAT degradation by repressing TRIM21-mediated GNPAT ubiquitination, ultimately promoting tumor growth in HCC xenografts. The gene discussed is GNPAT; the disease is hepatocellular carcinoma.